| Methods |
2‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= mean sitting SBP/DBP of 150‐179/<90 mm Hg after run‐in; 6‐week double‐blind treatment |
| Participants |
Telmisartan 20 mg: n=206(87 males,119 females); mean age=63.0(11.5) years: baseline sitting SBP=163.5(8.0) mm Hg, DBP=83.7(5.2) mm Hg, HR=72.4(10.0) bpm;
Telmisartan 40 mg: n=210(87 males,123 females); mean age=62.7(10.8) years: baseline sitting SBP=162.7(8.2) mm Hg, DBP=83.4(4.6) mm Hg, HR=72.1(9.9) bpm;
Telmisartan 80 mg: n=207(91 males,116 females); mean age=62.5(10.9) years; baseline sitting SBP=162.4(8.2) mm Hg, DBP=83.2(5.1) mm Hg, HR=72.4(9.9) bpm;
Placebo: n=211(90 males,121 females); mean age=63.6(10.2) years; baseline sitting SBP=163.3(7.8) mm Hg, DBP=83.5(5.1) mm Hg, HR=72.2(9.9) bpm |
| Interventions |
Telmisartan 20 mg once daily;
Telmisartan 40 mg once daily;
Telmisartan 80 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
Used SBP data only; BP change reported, SD of change not reported, endpoint BP and SD not reported, baseline SD reported; imputed overall trial mean SBP SD of change since SBP levels used as inclusion criteria; BP data from text, p. 1035; Jadad score=3; funding source= Boehringer Ingelheim |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
